As of 2025-07-04, the EV/EBITDA ratio of Cure Pharmaceutical Holding Corp (CURR) is 0.71. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CURR's latest enterprise value is -21.49 mil USD. CURR's TTM EBITDA according to its financial statements is -30.38 mil USD. Dividing these 2 quantities gives us the above CURR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 6.6x - 9.5x | 8.1x |
| Forward P/E multiples | 6.6x - 8.7x | 8.1x |
| Fair Price | (8.16) - (2.31) | (6.26) |
| Upside | -884.3% - -321.8% | -701.8% |
| Date | EV/EBITDA |
| 2025-06-26 | 0.99 |
| 2025-06-25 | 0.99 |
| 2025-06-24 | 1.01 |
| 2025-06-23 | 1.05 |
| 2025-06-20 | 1.10 |
| 2025-06-18 | 1.14 |
| 2025-06-17 | 1.14 |
| 2025-06-16 | 1.11 |
| 2025-06-13 | 1.10 |
| 2025-06-12 | 1.07 |
| 2025-06-11 | 1.07 |
| 2025-06-10 | 1.05 |
| 2025-06-09 | 1.05 |
| 2025-06-06 | 1.05 |
| 2025-06-05 | 1.05 |
| 2025-06-04 | 1.05 |
| 2025-06-03 | 1.05 |
| 2025-06-02 | 0.99 |
| 2025-05-30 | 1.00 |
| 2025-05-29 | 1.00 |
| 2025-05-28 | 1.04 |
| 2025-05-27 | 1.06 |
| 2025-05-23 | 1.05 |
| 2025-05-22 | 1.04 |
| 2025-05-21 | 1.04 |
| 2025-05-20 | 0.96 |
| 2025-05-19 | 0.87 |
| 2025-05-16 | 0.82 |
| 2025-05-15 | 0.81 |
| 2025-05-14 | 0.73 |
| 2025-05-13 | 0.66 |
| 2025-05-12 | 0.71 |
| 2025-05-09 | 0.61 |
| 2025-05-08 | 0.57 |
| 2025-05-07 | 0.57 |
| 2025-05-06 | 0.56 |
| 2025-05-05 | 0.50 |
| 2025-05-02 | 0.47 |
| 2025-05-01 | 0.47 |
| 2025-04-30 | 0.45 |
| 2025-04-29 | 0.44 |
| 2025-04-28 | 0.44 |
| 2025-04-25 | 0.39 |
| 2025-04-24 | 0.38 |
| 2025-04-23 | 0.41 |
| 2025-04-22 | 0.44 |
| 2025-04-21 | 0.48 |
| 2025-04-17 | 0.39 |
| 2025-04-16 | 0.43 |
| 2025-04-15 | 0.41 |